Finzati - Logo
NRSN logo

NeuroSense Therapeutics Ltd.

NRSN • Biotechnology
$0.00
— 0.00 (0.00%)
EarningsLatest report: Dec 31, 2025
WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$17.51M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Weak liquidity · 0.31Weak profitability
Financial data as of: Dec 31, 2025, 12:00 AM UTCLast earnings update: Apr 6, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.00
Change0.00%
Market Cap$17.51M
52W Range0.63 - 2.19
Beta1.54
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq-0.11
Current Ratio0.31
Quick Ratio0.31
Volume1.38M

Investment DNA

How strong this company looks for long-term investors

33
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
20/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
50/100
Why this score▼
Weak liquidity · 0.31Weak profitability
Analyst view
No analyst data available now.

Company Overview

IPO: 12/9/2021
Industry: Biotechnology
P/B i: -12.56
Debt / Equity i: -0.11
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score4 / 20
Debt / Equity: -0.11
Current Ratio: 0.31
Quick Ratio: 0.31
Status: HighRisk

Warnings

  • Weak Liquidity
  • Weak quick ratio

Insider Transactions

Recent executive and insider activity

Eisenberg Or
Transaction: 06/16/2026
BUY
Change
+250,000
Price
$0.80
Filing
06/17/2026
Type
BUY
Ben-Noon Alon
Transaction: 06/16/2026
BUY
Change
+250,000
Price
$0.80
Filing
06/17/2026
Type
BUY
Eisenberg Or
Transaction: 03/26/2026
BUY
Change
+200,000
Price
Not reported
Filing
04/01/2026
Type
BUY